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Movement disorders can be primarily divided into hypokinetic and hyperkinetic. Most 
of the hypokinetic syndromes are associated with the neurodegenerative disorder 
Parkinson’s disease (PD). By contrast, hyperkinetic syndromes encompass a broader 
array of diseases, including dystonia, essential tremor, or Huntington’s disease. The 
discovery of effective therapies for these disorders has been challenging and has also 
involved the development and characterization of accurate animal models for the 
screening of new drugs. Zebrafish constitutes an alternative vertebrate model for the 
study of movement disorders. The neuronal circuitries involved in movement in zebrafish 
are well characterized, and most of the associated molecular mechanisms are highly 
conserved. Particularly, zebrafish models of PD have contributed to a better under-
standing of the role of several genes implicated in the disease. Furthermore, zebrafish 
is a vertebrate model particularly suited for large-scale drug screenings. The relatively 
small size of zebrafish, optical transparency, and lifecycle, are key characteristics that 
facilitate the study of multiple compounds at the same time. Several transgenic, knock-
down, and mutant zebrafish lines have been generated and characterized. Therefore, 
it is central to critically analyze these zebrafish lines and understand their suitability 
as models of movement disorders. Here, we revise the pathogenic mechanisms, 
phenotypes, and responsiveness to pharmacotherapies of zebrafish lines of the most 
common movement disorders. A systematic review of the literature was conducted by 
including all studies reporting the characterization of zebrafish models of the move-
ment disorders selected from five bibliographic databases. A total of 63 studies were 
analyzed, and the most relevant data within the scope of this review were gathered. 
The majority (62%) of the studies were focused in the characterization of zebrafish 
models of PD. Overall, the zebrafish models included display conserved biochemical 
and neurobehavioral features of the phenomenology in humans. Nevertheless, in light 
FiguRe 1 | Representative images of zebrafish at embryonic  
(a), larval (B), and adult (c) stage.
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of what is known for all animal models available, the use of zebrafish as a model for drug 
discovery requires further optimization. Future technological developments alongside 
with a deeper understanding of the molecular bases of these disorders should enable 
the development of novel zebrafish lines that can prove useful for drug discovery for 
movement disorders.
Keywords: drug discovery, hyperkinesia, hypokinesia, movement disorders, zebrafish models
iNtRODuctiON
Movement disorders are a heterogeneous group of neurological 
conditions characterized by the inability to produce or control 
movement. The typical clinical features include either paucity of 
voluntary movements, referred to as hypokinesia, bradykinesia 
and akinesia, or excess of movement, commonly denoted as 
hyperkinesia, dyskinesia, and abnormal involuntary movements 
(1). These two major groups have been dynamic, including 
different categories over time. Most movement disorders lack 
effective pharmacological therapies, because their complex 
etiology and pathological mechanisms remain largely unknown. 
This complicates the development of adequate animal models 
and, ultimately, of therapeutic compounds. In this context, 
zebrafish (Danio rerio) (Figure 1) has become an attractive tool 
for drug discovery. Zebrafish presents a compromise between 
the scalability of invertebrate models and overall homology 
to vertebrates. In the last 20 years, several zebrafish models of 
brain disorders have been generated (2). Many discoveries were 
reported, but an overall analysis of zebrafish as an alternative 
model of movement disorders is lacking. Therefore, the scope 
of this review was to systematically analyze the latest develop-
ments in the generation and characterization of zebrafish models 
of the most common movement disorders. This highlights the 
translational value of zebrafish to model these diseases and, ulti-
mately, for drug discovery. The pathogenic mechanisms, disease 
hallmarks, phenotypic effects of mutations or neurotoxins, and 
responsiveness to pharmacological interventions are covered 
for zebrafish models of two hypokinetic and five hyperkinetic 
disorders (Table 1).
Zebrafish as a model for translational 
Research
The utilization of zebrafish for drug discovery increased in the 
beginning of the twenty-first century (Figure  2) (3, 4). Due 
to its small size and fast reproduction, zebrafish is suitable for 
large-scale in  vivo assays. Drug administration is facilitated 
through the aqueous environment, and the efficacy, bioavail-
ability and toxicity can be readily determined. Importantly, 
zebrafish is a vertebrate, in contrast to other commonly used 
organisms, such as Drosophila melanogaster or Caenorhabditis 
elegans, in which the anatomical similarity with humans is 
much lower (5). The optical transparency is another advantage 
of this teleost, as it enables the direct observation of cellular 
and physiological processes in vivo and in real time. These and 
other practical features rendered zebrafish the mainstream 
model for investigation in developmental biology. In addi-
tion, it is now also widely used as a disease model and, more 
recently, it became an important tool for the screening of drugs 
(Figure 3) (6).
Despite the evident differences between fish and mammals, 
zebrafish hold genomic and physiological homology to humans 
(7). Moreover, the genome of zebrafish is sequenced and available 
for annotation in databases. The genome of zebrafish includes 
orthologs of 71% of human genes, and a high degree of conserva-
tion in the functional properties of many of the encoded proteins 
(8). Physiological and anatomical homology is also evidenced in 
most of the organs, including the nervous system (7). The basic 
anatomical structure, the cellular populations, and the chemistry 
of the zebrafish and human nervous system are evolutionarily 
conserved. The nervous system of zebrafish is anatomically 
divided into the fore-, mid-, and hindbrain, including the 
diencephalon, telencephalon, cerebellum, and spinal cord (2, 6). 
The blood–brain barrier (BBB) is structurally and functionally 
similar to that of higher vertebrates and developed by 3 days post 
fertilization (dpf) (9, 10).
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Dissection of the monoaminergic  
System in Zebrafish
Specifically, the monoaminergic system is involved in the adjust-
ment of movement and is predominantly conserved in vertebrates 
(Figure 4) (11). The tyrosine hydroxylase (TH) is an important 
marker of catecholaminergic neurons. Two genes, th1 and th2, 
encode the TH enzyme in zebrafish, and both proteins are highly 
similar to the mammalian TH (12). The neuronal populations that 
express TH1 can be found in the olfactory bulb, telencephalon, 
diencephalon, locus coeruleus, and caudal lobe (13). The neu-
rons that express TH2 are found in the ventral preoptic region, 
hypothalamus and colocalize with TH1-positive neurons in the 
diencephalic dopaminergic cluster. The dopamine transporter 
(DAT) is also detected in this neuronal population (14). The 
major difference of the zebrafish catecholaminergic system is the 
absence of dopaminergic neuronal populations in the midbrain. 
The diencephalic dopaminergic cluster located in the posterior 
tuberculum of zebrafish has been suggested to be the functional 
homolog of substantia nigra in mammals (15). Like in mammals, 
the noradrenergic population is predominantly located in the 
locus coeruleus of zebrafish. In turn, the catecholamines, dopa-
mine and noradrenaline, are detectable in zebrafish larvae with 
5 dpf (16). Zebrafish encode one monoamine oxidase (MAO) 
with homology to the human MAO-A and MAO-B, and two 
putative catechol-o-methyl transferases (17, 18). The catechola-
minergic receptors and transporters are also conserved among 
vertebrates. Eight subtypes of the dopamine receptor (17), five 
alpha-2-adrenergic receptors, and one noradrenaline transporter 
(19) have been identified in zebrafish so far.
The serotonergic and histaminergic systems of zebrafish also 
present homologies with the corresponding circuits in mammals. 
The zebrafish serotonergic neuronal groups can be found in the 
raphe nuclei, pretectum, posterior paraventricular organ, vagal 
lobe, and reticular formation (20). Particularly, the serotonergic 
pretectal and paraventricular neuronal populations are not found 
in higher vertebrates. Three orthologs of the mammalian sero-
tonin receptors have been identified in the genome of zebrafish, 
along with two genes, slc6a4a and slc6a4b, that encode serotonin 
transporters (21, 22). The zebrafish histaminergic system consists 
of a posterior hypothalamic neuronal cluster, from which all his-
taminergic projections derive (11). Histamine can be detected at 
100 hpf (23), and three histamine receptors have been identified 
in zebrafish (24).
Overall, the expression of monoaminergic proteins and the 
spatial distribution of monoaminergic neuronal populations are 
well characterized. Although zebrafish suffered genome duplica-
tion, it seems that the distribution of the duplicated proteins 
is complementary to that observed in mammals. This helps to 
explain why, despite the consistent differences, the drugs that 
target transporters, receptors or enzymes involved in the modula-
tion of neurotransmitters have rather conserved effects (25, 26).
metHODS
The aim of this review was to analyze the studies reported to 
date on the use of zebrafish models for movement disorders, 
FiguRe 3 | Schematic representation of the drug screening process in zebrafish. The zebrafish line is generated with genetic or chemical tools (a), is incubated 
with compounds from the library of small molecules (B), and is then phenotypically characterized (c).
FiguRe 2 | Timeline of the use of zebrafish as a model for the study of movement disorders and drug discovery. The publication year of the first study  
describing a zebrafish model of the movement disorder is highlighted. (#) Number of studies published to date.
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and assess their potential for modeling the human patholo-
gies. To achieve this, we conducted a systematic search of the 
literature using BiomedCentral, EBSCO host, PubMed/Medline, 
ScienceDirect, and Web of knowledge, in August and September 
2017. The following search strategy was used for each of the 
five bibliographic databases: Title, abstract, keywords, or topic: 
(“Parkinson’s disease” OR “Parkinsons disease” OR “parkinson-
ism”) AND (“zebrafish”); (“progressive supranuclear palsy” 
FiguRe 4 | Neuronal clusters that modulate movement in vertebrates. The approximate anatomical location of the dopaminergic (orange), histaminergic  
(purple), noradrenergic (blue), and serotonergic (green) regions are represented for human (a), rodent (B), and zebrafish (c) brains.
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OR “supranuclear palsy”) AND (“zebrafish”); (“dystonia” OR 
“dystonic”) AND (“zebrafish”); (“Tremor” OR “Tremors”) AND 
(“zebrafish”); (“Tourette’s syndrome” OR “Tourettes syndrome”) 
AND (“zebrafish”); (“Huntington’s disease” OR “Huntingtons 
disease”) AND (“zebrafish”); (“Rett syndrome” OR “Rett” 
OR “RTT”) AND (“zebrafish”). All dates were included in the 
search criteria. Only published, peer-reviewed studies written in 
English were considered. The studies with the description of the 
phenomenology of zebrafish models of movement disorders were 
included in the review, through scrutiny of the title and abstract 
of the papers identified during the systematic search. Studies 
with no description of the pathological mechanisms AND/OR 
phenotypes of the diseases were excluded from analysis.
For Parkinson’s disease (PD), a total of 39 studies (Figure 2) 
met the inclusion criteria, from 110 returned by BiomedCentral, 
111 by EBSCO host, 221 by PubMed/Medline, 4,015 by Science-
Direct, and 181 by Web of knowledge. For progressive supranu-
clear palsy (PSP), 1 study fulfilled the inclusion criteria, from 8 
returned by BiomedCentral, 2 by EBSCO host, 1 by PubMed/
Medline, 207 by ScienceDirect, and 2 by Web of knowledge. 
For dystonia, 8 studies were in agreement with the inclusion 
criteria, from 15 returned by BiomedCentral, 7 by EBSCO 
host, 11 by PubMed/Medline, 363 by ScienceDirect, and 15 
by Web of knowledge. For tremor, 1 study met the inclusion 
criteria, from 23 returned by BiomedCentral, 6 by EBSCO host, 
8 by PubMed/Medline, 618 by ScienceDirect, and 9 by Web of 
knowledge. For Tourette’s syndrome, no study fulfilled the inclu-
sion criteria, from 7 returned by BiomedCentral, 1 by PubMed/
Medline, 245 by ScienceDirect, and 2 by Web of knowledge. 
For Huntington’s disease (HD), 9 studies were in line with the 
inclusion criteria, from 54 returned by BiomedCentral, 22 by 
EBSCO host, 31 by PubMed/Medline, 964 by ScienceDirect, 
and 52 by Web of knowledge. Finally, for Rett syndrome 
(RTT), 5 studies met the inclusion criteria, from 20 returned by 
BiomedCentral, 5 by PubMed/Medline, 638 by ScienceDirect, 
and 13 by Web of knowledge.
ZeBRaFiSH aS a mODel OF 
HyPOKiNetic mOvemeNt DiSORDeRS
Parkinson’s disease and parkinsonism represent the most fre-
quent hypokinetic syndromes. These include akinesia (inability 
to initiate voluntary movements), bradykinesia (slowness of 
voluntary movements), gait and balance disturbances (falls), 
freezing phenomenon (absence or marked reduction of forward 
stepping during walking), and rigidity (resistance to externally 
imposed joint movements).
Parkinson’s Disease
Parkinson’s disease is the most prevalent movement disorder, 
affecting 100–200 per 100,000 people (27). The etiology of PD is 
a combination of genetic and environmental factors that, at some 
point during disease progression, lead to dopaminergic cell loss 
in the substantia nigra pars compacta and to the accumulation 
of protein inclusions known as Lewy bodies. These inclusions 
are primarily composed of the protein α-synuclein (Table  1). 
Mutations in the alpha-synuclein (snca), leucine-rich repeat 
kinase 2 (lrrk2), vps35, PTEN induced putative kinase 1 (pink1), 
parkinsonism associated deglycase (dj-1), and parkin RBR E3 
ubiquitin protein ligase (parkin) are associated with familial 
cases. However, the vast majority of the cases (~90–95%) are 
affected by sporadic PD. The treatment of motor symptoms aims 
at replacing dopamine and includes levodopa, among other 
dopaminergic modulators (Table 1). There are still no disease-
modifying agents for PD, but several drugs are under clinical 
trials.
Chemical Zebrafish Models of PD
1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-
Induced Models
Parkinson’s disease is the most studied movement disorder in 
zebrafish (Table 2). The effects of exposure to MPTP, known to 
cause loss of dopaminergic neurons and parkinsonism in humans 
(28), have been studied in zebrafish at all developmental stages 
(embryonic, larval, and adulthood). MPTP causes specific loss of 
dopaminergic neurons, a decrease of the dopamine, norepineph-
rine, and serotonin levels, and motility impairments in zebrafish 
larvae (29–32). By labeling monoaminergic neurons with GFP, 
Wen et al. (33) showed that the toxic effects of MPTP are more 
severe in the dopaminergic neurons located in the posterior 
tuberculum of the ventral diencephalon, corresponding to the 
mammalian midbrain dopaminergic neurons (33). Other neu-
ronal clusters, including the serotonergic, also seem to be affected, 
but in less extent (32). By contrast, MPP+, the metabolite of 
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MPTP, does not affect the serotonergic cluster, indicating a more 
specific action (32). MPP+ inhibits the multi-subunit enzyme 
complex I of the mitochondrial electron chain and impairs 
mitochondrial respiration (34). The subacute exposure to a 
low dose of MPP+ causes dramatic retrograde mitochondrial 
transport, before the appearance of neuronal and locomotor 
changes in zebrafish larvae (35). This suggests that MPP+ dam-
ages the mitochondria that are transported back to the cell body 
for degradation. This mechanism of bioenergetic homeostasis 
seems to be impaired at higher concentrations of MPP+. The 
MPTP-induced parkinsonian-like phenotype can be reverted by 
l-deprenyl (selegiline), an MAO-B inhibitor, and nomifensine, 
a DAT inhibitor (29, 30, 32). This indicates that the transport 
of MPTP and its conversion into the active metabolite, MPP+, 
is mediated by the same mechanisms in zebrafish and in mam-
mals (34). Although selegiline is used as an anti-parkinsonian 
agent, its restorative effects in MPTP-lesioned zebrafish do not 
totally mimic the therapeutic effects in PD patients.
In adult zebrafish, MPTP induces a reduction of the levels 
of dopamine and norepinephrine, which results in marked 
decrease of the motor performance (31, 36). MPTP-lesioned 
adult zebrafish exhibit a significant decrease of the swimming 
velocity (bradykinesia), an erratic swimming pattern and 
increase of the freezing episodes (dyskinesia) (37). Strikingly, 
there is no reduction in the number of dopaminergic neurons, 
neither the activation of pathways that lead to cell death (31, 36). 
In mice, the activity of the TH decreases after exposure to 
MPTP (38). This could in part explain the loss of dopamine and 
norepinephrine in zebrafish, despite the lack of cellular death. 
In turn, MPTP could cause a transient loss of function of the 
dopaminergic neurons, instead of its death. A proteomic analysis 
in MPTP-lesioned zebrafish revealed altered transcriptional 
regulation of several genes, including lrrk2, dj-1, park2, and 
pink1. In addition, the expression of 73 proteins, some of which 
associated with neurological pathways, was also changed (37). 
For instance, the neurofilament light polypeptide-like (NEFL) 
protein, involved in the glutamatergic and GABAergic signaling 
in presynaptic nerve terminals, was found downregulated in the 
brain of MPTP-lesioned zebrafish. As demonstrated in zebrafish 
larvae, selegiline induces recovery of the PD-like symptoms 
in MPTP-lesioned adult zebrafish (37). On the other hand, 
adult zebrafish submitted to an MPP+ injection do not exhibit 
abnormal phenotype, in contrast to zebrafish larvae (31). MPP+ 
cannot cross the mammalian BBB (39), suggesting that in adult 
zebrafish the mature BBB prevents the entry of MMP+ into the 
central nervous system (CNS). The differences observed in the 
several developmental stages could result from a lower sensitiv-
ity of adult zebrafish to the neurotoxin. The access of MPTP to 
the brain is very different in each of the developmental stages, 
which in part could result from the distinct routes of administra-
tion adopted. Larvae were exposed to the neurotoxin through 
the water, because of its extreme permeability, whereas, adults 
received a single intramuscular or intraperitoneal injection.
6-Hydroxydopamine (6-OHDA)-Induced Models
6-Hydroxydopamine is a hydroxylated compound of dopamine 
that has been extensively used to induce dopaminergic lesions 
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in rodents (34). Intramuscular injection of 6-OHDA causes a 
decrease of the dopamine and norepinephrine levels in adult 
zebrafish (36). Motor impairments are also observed, despite the 
lack of loss of dopaminergic neurons. By contrast, when admin-
istered into the ventral diencephalon of adult zebrafish, 6-OHDA 
induces significant ablation (>85%) of dopaminergic neurons in 
the posterior tuberculum and two other dopaminergic clusters, 
causing bradykinesia (40). The neuronal population in the olfac-
tory bulb is one of the clusters affected. This mimics the phenotype 
in rats that exhibit olfactory impairments when lesioned with 
6-OHDA into the substantia nigra (41). The inability to cross the 
BBB, explains the different phenotypes observed when 6-OHDA 
is administered intramuscularly or intracranially in zebrafish. 
A recovery of the dopaminergic neurons was observed 30 days 
post-lesion, which can be attributed to the neuro-regenerative 
capacity of the adult zebrafish brain (42). Therefore, the highly 
regenerative nature of zebrafish compromises the study of the 
progressive degenerative process in PD. On the other hand, the 
intracerebral administration of 6-OHDA revealed to be a labori-
ous and meticulous protocol.
In the zebrafish larval stage, exposure to 6-OHDA in the water 
induces a decrease in the expression of TH, reduction in the 
locomotor activity and anxiogenic behavior (43). The locomo-
tor impairments can be rescued by vitamin E, minocycline, and 
levodopa + carbidopa, the most effective drug used in patients 
with PD. Vitamin E is also able to normalize the expression of TH, 
while minocycline attenuates the increase of the expression of 
TNF-α and cd11b mRNA in 6-OHDA-lesioned zebrafish larvae. 
Vitamin E has antioxidant properties (44) and minocycline has 
shown anti-neuroinflammatory activity in rodents (45). This sug-
gests that the oxidative stress and inflammatory process induced 
by 6-OHDA in zebrafish larvae share functional features with 
mammals.
Paraquat-Induced Models
Chronic exposure to pesticides, used in agriculture, has been 
recognized as a risk factor for development of parkinsonian 
syndromes. Paraquat induces oxidative stress and cytotoxicity 
in neurons (46). This herbicide is structurally similar to MPP+ 
and is associated with increased risk of developing PD (47). 
In adult zebrafish, the systemic administration of paraquat causes 
locomotor changes, but no anxiety-like behavior (48). In a differ-
ent study, anxiolytic and aggressive behavior were observed, but 
no motor impairments in paraquat-lesioned adult zebrafish (49). 
While the former mimics the locomotor impairments, the later 
resembles the anxiogenic behavior in paraquat-lesioned rodents 
(50–52). The authors suggested that the results may be influen-
ced by the genotype or gender of fish. Adult zebrafish lesioned 
with paraquat also reveal impairments in spatial memory, a 
decrease in the ratio of DOPAC/dopamine levels, a decrease in 
the expression of DAT, lowered mitochondrial viability, and an 
increase in the expression of antioxidant enzymes (48, 49). TH 
expression and reactive oxygen species (ROS) levels were unal-
tered. Despite the lack of cellular hallmarks of PD, the neurobe-
havioral syndrome in zebrafish is very similar to the one observed 
in paraquat-lesioned rodents (50, 51, 53). The neurotoxic effects 
of paraquat in this model are also variable (50, 51, 54).
Alternatively, when added to the water, paraquat seems to 
induce no parkinsonian-like phenotypes in larvae and adult 
zebrafish. These exhibit a normal number of dopaminergic 
neurons, normal behavior, and no developmental defects (31). 
Instead, when the LC50 of paraquat is used, zebrafish larvae 
exhibit a reduction of the dopamine and serotonin levels, 
activation of antioxidant and oxidative stress related genes, 
and distinct macrophage activation and migration (55, 56). 
In addition, significant increase of apoptotic cells in the head, 
trunk, and tail, and motor deficits are observed. However, the 
authors did not rule out general toxicity, leaving doubts about 
the specificity of the phenotypes observed. In addition, the 
toxic effects of paraquat seem to have high variability. Zebrafish 
larvae with 48 hpf exposed to 600 mg/L of paraquat do not show 
morphological defects, while 0.04 and 100  mg/L of paraquat 
were determined as LC50 in zebrafish larvae with 18 and 72 
hpf, respectively. The successful induction of dopaminergic 
neuronal death by pesticides in rodents has also been strik-
ing. While paraquat is associated with high variability (57), 
rotenone induces weakly reproducible phenotypes and high 
mortality rates (58).
Rotenone-Induced Models
Exposure to rotenone has been linked to a higher risk of PD 
(47). In zebrafish, the phenotypes induced by rotenone are 
incongruent. One study found no cellular or behavioral parkin-
sonian-like phenotypes in larvae and adult zebrafish exposed 
to rotenone (31). By contrast, using the same concentration of 
the pesticide, time of exposure, and route of administration, 
a different study reported that adult zebrafish have decreased 
levels of dopamine and TH, deficits in motor function, anxiety 
and depression-like behavior, and olfactory dysfunction (59). 
Differences in TH expression and motor performance could be 
justified by the different protocols used to determine each of 
the parameters. In one study, the authors determined mRNA 
expression of TH by in situ hybridization and locomotor per-
formance through the mean velocity of swimming. In the other, 
the authors analyzed TH expression by western blot and motor 
capacity through monitorization of freezing, swimming at low 
speed, and swimming at high speed. The difference between 
rotenone and vehicle treated zebrafish was detectable only at 
high speed swimming. The phenotypes observed are character-
istic of PD patients (60, 61), and some mirror the phenotypes 
found in rodents (62, 63).
Other Neurotoxic Agents
Other less conventional methods have been used to induce 
dopa minergic neurotoxicity in zebrafish. This is the case of 
the transgenic line that expresses the reporter cyan fluorescent 
protein and the nitroreductase enzyme under the control of the 
dat promoter [Tg(dat:CFP-NTR)]. When transgenic larvae are 
exposed to metronidazole, the nitroreductase metabolizes it into 
a cytotoxic product that activates the apoptotic pathway and 
induces dopaminergic cell loss. The process can be monitored in 
real time, by detection of the reporter protein. Tg(dat:CFP-NTR) 
zebrafish larvae exposed to metronidazole show a reduction of 
the number of neurons in several dopaminergic clusters. This 
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coincides with a decrease of dopamine levels and the appear-
ance of locomotor impairments (64). The zebrafish line seems to 
maintain a persistent decrease of dopaminergic neurons that lasts 
longer than the other toxin-induced models.
Alternatively, a recent study showed that titanium dioxide 
nanoparticles (TiO2 NPs) cause parkinsonian-like phenotypes in 
zebrafish larvae (65). Exposure to TiO2 NPs induces premature 
hatching and abnormal development, but no lethality. TiO2 NPs 
accumulate in the brain of zebrafish larvae, resulting in the gen-
eration of ROS, loss of dopaminergic neurons, cell death in the 
hypothalamus and locomotor impairments. An increase in the 
expression of pink1, parkin, and uchl1 genes was also observed. 
Surprisingly, the authors also described an increase of the expres-
sion of the α-synuclein gene. Since zebrafish lack the ortholog of 
the human α-synuclein, the authors must have wanted to refer 
to the other two synucleins expressed in zebrafish (66). In rats, 
TiO2 NPs accumulate in the brain, stimulate oxidative stress and 
inflammatory responses, and cause impairments in the CNS (67). 
Despite the similarities of the phenotypes observed in zebrafish 
with the molecular and cellular mechanisms in PD, there is still 
no association of TiO2 NPs with increased risk of PD.
Genetic Zebrafish Models of PD
Synucleins
Among the several zebrafish genes with homology to human 
PD genes, an ortholog of the human α-synuclein appears not 
to be present in the zebrafish genome (68). Instead, zebrafish 
express three synuclein isoforms, β-, γ1-, and γ2-synucleins, that 
seem to compensate the absence of α-synuclein. Functionally, 
the zebrafish γ1-synuclein appears to be the closest to the 
human α-synuclein. Knockdown of the β- or γ1-synucleins 
induces motor impairments in zebrafish, which are even more 
severe when the expression of both synucleins is abrogated 
(69). Zebrafish lacking both synucleins have an abnormal 
development of the dopaminergic system, including delayed 
differentiation of dopaminergic neurons and reduced levels of 
dopamine. The phenotype can be reverted by the expression of 
human α-synuclein. Strikingly, the knockdown of the zebrafish 
β- and γ1-synucleins results in phenotypes that recapitulate 
the aspects observed in rodents lacking all synucleins (70–73). 
In zebrafish, overexpression of γ1-synuclein leads to the forma-
tion of neuronal aggregates and neurotoxicity, similarly to the 
human α-synuclein (74). On the other hand, downregulation 
of γ1-synuclein protects zebrafish from the toxicity of ziram. 
Exposure to ziram dramatically increases the risk to develop 
PD. This pesticide causes loss of dopaminergic neurons and 
impaired swimming behavior in zebrafish (74). Treatment with 
apomorphin recues the motor impairments. Moreover, CLR01, 
an inhibitor of amyloidogenic proteins self-assembly, protects 
zebrafish against ziram-induced neurotoxicity. These data sug-
gest that ziram might induce toxicity on dopaminergic neurons 
through the formation of γ1-synuclein toxic oligomers. Still, 
none of the above zebrafish lines exhibit as a severe phenotype 
as zebrafish overexpressing human α-synuclein. During embry-
onic development, this line presents neuronal apoptosis, which 
results in severe deformities and death within 48–72  h (75). 
The neurotoxic effect of α-synuclein is mediated by the inhibi-
tion of the ubiquitin proteasome system and accumulation of 
α-synuclein. Treatment with CLR01 reduces the aggregation of 
α-synuclein and neuronal apoptosis, increasing viability. The 
devastating effects of the overexpression of human α-synuclein 
may hinder the successful generation of transgenic zebrafish 
lines. Perhaps, by restricting the expression of the protein to the 
dopaminergic neurons or to a transient manner could decrease 
the lethality, while maintaining the pathological mechanisms.
PTEN Induced Putative Kinase 1 (PINK1)
The gene PINK1 is implicated in genetic and sporadic cases 
of PD. Morpholino knockdown of the zebrafish PINK1 
ortholog has added evidence to the importance of this gene 
in the control of oxidative stress and mitochondrial function. 
Downregulation or total abrogation of the expression of PINK1 
results in mitochondrial dysfunction that leads to augmented 
levels of ROS and activation of the apoptotic signaling path-
way in zebrafish (76). The PINK1 null mutant zebrafish line 
also presents mitochondrial impairments (77). The zebrafish 
Pink1 influences the expression of other proteins that are 
critical contributors to the pathogenic process. For instance, 
the activity of the mitochondrial protein GSK3β is increased 
and its inhibition, with LiCl and SB216763, partially rescues 
the phenotypes in PINK1 morphant zebrafish (76). TigarB, 
the zebrafish ortholog of the human glycolysis and apoptosis 
regulator Tigar, is also markedly increased in Pink1 null 
mutants (77). Tigar has been identified as a negative regulator 
of mitophagy, considered to be crucial in the pathogenesis of 
early-onset PD (78). The expression of other 177 genes, from 
the hypoxia-inducible factor (HIF) signaling, TGFβ-signaling, 
and several key toxicological responses (mitochondrial dys-
function, RAR activation, and biogenesis of mitochondria), 
is also altered (79). Particularly, the HIF pathway is the most 
affected pathway in PINK1 knockdown zebrafish. This is 
known to participate in the regulation of oxidative stress and 
neuronal differentiation in vitro (80, 81).
Whereas, the molecular mechanisms seem to be consistent, 
the phenotypes induced by the alteration of Pink1 expression 
in zebrafish vary. PINK1 morphant zebrafish exhibit general 
developmental delay, severe mispatterning of the axonal scaf-
fold, and moderate decrease of the number of neurons, mainly 
in the dopaminergic system (76). The phenotype could be 
rescued by wild-type human pink1 mRNA. Further support-
ing these results, PINK1 knockdown zebrafish show changes 
in neuronal patterning and axonal projections (82). This line 
also presents mild loss of dopaminergic neurons in the dien-
cephalon, which leads to spontaneous or evoked locomotor 
impairments. Motor performance could be rescued by the 
dopamine agonist SFK-38393. Moreover, the expression of 
exogenous PINK1 rescued all phenotypes. By contrast, a sub-
sequent study reported no morphological or behavioral deficits 
in PINK1 morphant zebrafish (83). Instead, increased vulner-
ability to MPTP-induced toxicity was observed. The authors 
described a reduction in the expression of both, th1 and th2 
mRNA forms, but normal levels of dat mRNA. Although there 
11
Vaz et al. Zebrafish: Drug Discovery in Movement Disorders
Frontiers in Neurology | www.frontiersin.org June 2018 | Volume 9 | Article 347
was a mild decrease in the number of TH-positive neurons 
in the dopaminergic diencephalic cluster, the normal levels 
of dat suggest that the downregulation of PINK1 may cause a 
decline in important mRNAs and proteins, instead of neuronal 
death. Still, the increased susceptibility to MPTP strengthens 
the importance of PINK1 in oxidative stress. In accordance, 
the exposure to H2O2 dramatically increases the expression of 
pink1 mRNA in zebrafish, which can be reverted by the anti-
oxidant l-glutathione reduced (84). In PINK1 mutant zebrafish 
larvae, the loss of dopaminergic neurons is more evident and 
accompanied by marked microglial activation (77). In fact, 
PINK1 deficiency causes different phenotypes in mammals, as 
well. In humans, mutations in PINK1 can result in early-onset 
PD and are associated with mitochondrial dysfunction (85). 
In turn, PINK1 knockout mice have a mild phenotype, with 
no neuronal death, no changes in the levels of striatal dopa-
mine, nor in the number and morphology of mitochondria 
(86). Interestingly, it seems that PINK1 knockdown zebrafish 
recapitulate better than mice the human phenotypes.
Parkin RBR E3 Ubiquitin Protein Ligase (Parkin)
Mutations in PINK1 and Parkin are implicated in mitochon-
drial dysfunction and seem to share several pathogenic mecha-
nisms in PD. Consistently, Parkin knockdown zebrafish exhibit 
a phenotype that resembles PINK1 knockdown zebrafish. 
Abrogation of the expression of Parkin leads to impaired mito-
chondrial function, specific loss of dopaminergic neurons in 
the posterior tuberculum, and increased sensitivity to the toxic 
effects of MPP+ (87). Neither the serotonergic nor the motor 
neurons are affected, and the extent of dopaminergic loss is 
not enough to cause behavioral defects. Parkin knockdown 
zebrafish present two important phenotypes, mitochondrial 
dysfunction and dopaminergic cells loss, described in PD 
patients with mutations in Parkin (88, 89). Once again, it 
seems that the zebrafish model mimics better than mice mod-
els the pathological mechanisms in humans. Parkin knockout 
mice do not show any robust morphological changes, neither 
increased susceptibility to MPP+ (90, 91). Notwithstanding, 
morpholino-mediated knockdown of the zebrafish Parkin 
generates very dissimilar phenotypes. In a different study, 
no loss of dopaminergic neurons, neither morphological nor 
behavioral alterations, was observed upon Parkin knockdown 
in zebrafish (92). This result may be the consequence of a 
partial ablation (around 50%) of Parkin expression. Still, this 
line maintained the increased vulnerability to stress-induced 
cell death. Importantly, the authors also described that the 
overexpression of Parkin in a transgenic zebrafish line pro-
tects from proteotoxic stress-induced cell death. Similarly to 
PINK1, Parkin is suggested to have a protective role in PD (93). 
In zebrafish, it seems that the presenilin-associated rhomboid-
like (PARL) protein is also part of the PINK1 and Parkin 
pathway. PARL is a component of the mitochondrial mem-
brane involved in mitochondrial morphology and apoptosis. 
Morpholino knockdown of both zebrafish paralogs, parla and 
parlb, results in high mortality, whereas loss of PARLb leads to 
the mildest phenotype (94). Loss of one of the PARL’s results 
in mild neurodegeneration and disarranged dopaminergic 
neurons. Although changes in survival were not reported, 
generalized cell death was observed. Interestingly, the pheno-
type can be rescued by human parl mRNA and by zebrafish 
and human pink1 mRNA. The PARL gene has been linked to 
familial cases of PD. PARL is suggested to be important in the 
normal trafficking and processing of PINK1 and Parkin in 
mitochondria (95).
DJ-1
Mutations in DJ-1 are associated with early-onset PD. The 
inactivation of DJ-1 in zebrafish leads to an increase in the 
expression of p53 and Bax, but no cellular or morphological 
changes (96, 97). Moreover, the concomitant knockdown of DJ-1 
and mdm2, a negative regulator of p53, results in dopaminergic 
neuronal death (96). This suggests that p53 may mediate cell 
loss in the absence of DJ-1. DJ-1 knockdown zebrafish exhibit 
loss of dopaminergic neurons after exposure to H2O2 and to the 
proteasome inhibitor MG132. The phenotype can be prevented 
with pharmacological inhibition of p53, by pifithrin-alpha 
(96, 97). This demonstrates that DJ-1 knockdown zebrafish are 
susceptible to programmed cell death and that DJ-1 may medi-
ate the stress response machinery. In accordance, DJ-1-deficient 
mice only exhibit dopaminergic cell death after toxin exposure 
(98). The p53-glycerylaldehyde-3-phosphate dehydrogenase 
(GAPDH)–Bax pathway has been suggested to be involved in PD 
(99, 100).
Leucine-Rich Repeat Kinase 2 (LRRK2)
The phenotypes of LRRK2 morphant zebrafish have been cha-
racterized. The first study describing the consequences of the 
inhibition of the expression of LRRK2, showed embryonic 
lethality and severe developmental defects, such as brain devel-
opmental retardation, in zebrafish (101). A more recent study, 
described neuronal loss, affecting the dopaminergic system, 
upregulation of the expression of β-synuclein, Park13, and SOD1, 
and β-synuclein aggregation in the CNS (102). The authors also 
described a wide range of organ abnormalities but did not report 
such overt toxicity as the former study. On the other hand, the 
deletion of the WD40 domain of LRRK2 (ΔWD40-LRRK2) 
causes little impact on embryonic development, in zebrafish 
(101). Instead, this mutant zebrafish line presents a reduction 
and disorganization of the axonal tracts, predominantly in 
the midbrain. In addition, significant loss of the diencephalic 
dopaminergic neurons and locomotor defects were observed. 
The phenotype can be rescued by zebrafish and human lrrk2 
mRNA overexpression. The administration of levodopa rescues 
the motor impairments, but not neurodegeneration, in line with 
the therapeutic effects in humans. Surprisingly, a subsequent 
study was not able to replicate the phenotypes described in the 
ΔWD40-LRRK2 zebrafish line (103). Nevertheless, it has been 
reported that mutations in the LRRK2-WD40 domain increase 
neuronal apoptosis under cellular stress (104). In mice, LRRK2 
knockout and G2019S LRRK2 transgenesis do not induce neu-
ropathological abnormalities, but LRRK2 seems to interfere with 
normal neurite outgrowth (105, 106).
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Other PD Genes
Genes implicated in atypical PD, have also been characterized 
in zebrafish. Park15 is caused by loss of function of the protein 
encoded by the gene fbxo7 (107). Morpholino knockdown of the 
zebrafish Fbxo7 ortholog results in abnormal patterning and loss 
of dopaminergic neurons, which lead to severe motor impair-
ments (108). Treatment with apomorphine, a dopamine agonist, 
can revert the locomotor defects. Surprisingly, the human 
fbxo7 mRNA failed to rescue the morphological phenotypes. 
This observation was justified with an atypical timing and loca-
lization of expression, as compared with the expression of the 
Fbxo7 endogenous zebrafish gene. Fbxo7 morphant zebrafish 
also exhibit developmental defects, as heart deformations, 
sug gesting that Fbxo7 must have an important role in zebrafish 
deve lopment. The zebrafish ortholog of another gene linked 
to atypical PD, atp13a2, has also shown a crucial role during 
embryonic development. Complete abrogation of the expres-
sion of ATP13A2 leads to embryonic lethality, whereas partial 
knockdown results in abnormal splicing of atp13a2 mRNA 
and obvious behavioral impairments (109). The results are in 
line with experiments in mice, which have also revealed the 
importance of ATP13A2 during the early stages of embryonic 
development and neurogenesis (110).
effect of Dopaminergic modulators in 
Zebrafish
When assessing the validity of an animal model, beyond the 
pathological hallmarks of the disease, it is important to explore 
the pharmacologically evoked changes. Studies that report such 
experiments in zebrafish models of PD are scarce, but there exist 
some reports exploring the effects of drugs known to modulate 
movement on healthy zebrafish. For instance, haloperidol and 
chlorpromazine, two dopamine receptor antagonists, have been 
tested on zebrafish larvae. The suppression of the dopaminergic 
signaling by both compounds induces akinetic-like behavior 
(111). Another study supporting these data showed that the 
selective dopamine agonists, SFK-38393 and quinpirole, increase 
motor activity (112). By contrast, the dopamine antagonists, 
SCH-23390 and haloperidol, decrease motor activity in zebrafish 
larvae. Interestingly, the non-selective dopamine agonist, 
apomorphine, and dopamine antagonist, butaclamol, induce 
biphasic dose-response patterns. This may be attributed to the 
action of the drugs on multiple dopaminergic receptors. On the 
other hand, the dopamine antagonists, SCH-23390 and halop-
eridol, induce different dose-response profiles dependent on 
the lighting conditions. The authors suggested that the blockade 
of dopamine receptors in the retinal ganglion cells may have 
perturbed the adaptation to light/dark conditions. Alternatively, 
the effects of haloperidol were studied in catalepsy (muscular 
rigidity). Similarly to rats, it was observed that haloperidol 
causes the increase of catalepsy in zebrafish (113). This can be 
reverted by bromocriptine and pramipexole, two dopamine 
agonists commonly used to improve rigidity. Importantly, this 
study introduced a new core motor symptom of PD on zebrafish, 
in alternative to bradykinesia. All the above-mentioned studies 
demonstrated that the drugs that target the dopaminergic system 
in mammals elicit similar outcomes in zebrafish, suggesting that 
the underlying mechanisms that regulate movement are shared 
by both models. Nevertheless, the demonstration that the phe-
notypes observed in zebrafish actually result from modulation of 
the dopaminergic pathway is needed.
Overall, chemical and genetic zebrafish models of PD 
repro duce several of the biochemical, neurochemical, morpho-
logical, and neurobehavioral features of the disease in humans. 
Importantly, the pharmacological response to drugs used in the 
clinic is also conserved. The limitations inherent to each model 
do not seem to surpass the limitations also described in rodents 
and, in some cases, zebrafish resemble better than rodents, the 
human features. Finally, the zebrafish genes orthologs to the 
human genes associated with PD seem to be particularly con-
served in terms of sequence and function, as well as, the role of 
the respective protein in the cellular pathways.
Other Parkinsonian Syndromes
Progressive supranuclear palsy is a PD-plus syndrome associated 
with tau neuropathology, which affects about 5–7 per 100,000 
people (114). The neuropathological hallmarks include the 
presence of neurofibrillary tangles (insoluble 4-repeat tau 
protein) or neuropil threads in the basal ganglia and brainstem. 
Neuronal loss is diffuse, affecting different neuronal structures 
(Table  1). Initially, the clinical presentation is heterogeneous 
but tends to develop to unsteady gait, bradykinesia, unexplained 
falls, and ocular motor deficits (vertical supranuclear gaze palsy 
is used to confirm the diagnose). Most of the cases of PSP are 
sporadic and associated with polymorphisms in the gene that 
encodes the tau protein, MAPT. Mutations in the MAPT gene 
have been identified in several familial cases, as well, but are 
rarer.
Recently, zebrafish was used to assess the functional and 
bio chemical consequences of a tau variant, p.A152T, identified 
to increase the risk of PSP in a cohort study (115). The A152T-
tau transgenic zebrafish exhibit increased accumulation and 
phosphorylation of tau, with formation of neurofibrillary tangles 
(Table 2). The phenotype possibly results from impairments in 
the proteasome system. The overexpression of A152T-tau also 
causes neurodegeneration, associated with behavioral deficits in 
zebrafish. The phenomenology is compatible with the phenotypes 
observed in A152T transgenic rodent models (116, 117). The use 
of zebrafish to model PSP is at its beginning and needs further 
developments. Nevertheless, the data described so far indicate 
that zebrafish models of PSP may exhibit several neuropatho-
logical hallmarks of the disease. Effective pharmacotherapeutic 
options for PSP are null at the moment, and zebrafish may help 
to boost the discovery of new drugs.
ZeBRaFiSH aS a mODel OF 
HyPeRKiNetic mOvemeNt DiSORDeRS
Hyperkinetic movement disorders have a more diverse phenom-
enology and include tremors, dystonia (sustained, repetitive, and 
patterned muscle contractions), tics (sudden, rapid, repetitive, 
and non-rhythmic movements), chorea (brief, irregular, abrupt, 
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and non-repetitive movements), and stereotypies (repetitive or 
ritualistic movements), among others.
Dystonia
Dystonia is a common and clinically heterogeneous disorder, 
which can be manifested as an isolated clinical condition 
(primary dystonias) or associated with other neurological 
disorders (secondary dystonias) (118). The cause is diverse 
and includes genetic and environmental factors (Table  1). 
This phenomenon is believed to result from malfunction of 
the basal ganglia and, consequently, abnormal plasticity of the 
sensorimotor cortex (119). The pharmacotherapy for dystonia 
is solely symptomatic, mostly empirical, and adapted to each 
case (Table 1) (120). In the last 5 years, zebrafish have been 
used to understand the mechanisms of dystonia.
Genetic Zebrafish Models of Dystonia
The most common cause of early-onset primary dystonia is a 
mutation in the TOR1A gene (121). In zebrafish, the ortholog 
gene, tor1, is not essential for early development of the motor 
system. The morpholino-mediated knockdown zebrafish 
line presents normal viability, morphology, development, 
and behavior (Table  3) (122). Zebrafish TOR1 may have an 
important role in later events, but the transient effect of 
morpholino-mediated knockdown did not allow to confirm 
this fact. Accordingly, in TOR1A knockout mice, the first 
phenotypic abnormalities are only observed in a later devel-
opmental stage (123). Other genes implicated in dystonia are 
involved in neuronal development and brain maturation in 
zebrafish. For instance, dystonia in early childhood can be 
caused by an autosomal recessive mutation in the pantothen-
ate kinase 2 (PANK2) gene (124). Morpholino knockdown of 
the zebrafish ortholog perturbs the neuronal development 
and brain morphology and induces hydrocephalus (125). The 
phenotype can be rescued by pantethine and coenzyme A. 
To further test the implication of mutations identified in the 
col6a3 gene of subjects with primary dystonia, a study found that 
morpholino knockdown of the zebrafish ortholog gene causes 
deficits in axonal outgrowth (126). The authors suggested 
that Col6a3 may participate in the structural organization of 
neurons. Therefore, its disruption can hamper the establish-
ment of correct neuronal circuitries and synaptic remodeling 
processes, during brain development and maturation. Finally, 
knockdown of the ortholog of the human Atp1a3 leads to brain 
ventricle dilation and depolarization of Rohon–Beard neurons 
in zebrafish (127). Although response to tactile stimuli and 
motility are altered, the dopaminergic neurons seemed to be 
unaffected. Mutations in the Atp1a3 are implicated in rapid-
onset dystonia parkinsonism (RDP) (128). Ventricle dilation 
is not observed in patients with RDP, but numerous symptoms 
reported in dystonic patients suggest the involvement of the 
somatosensory system. In turn, the depolarization of Rohon–
Beard neurons in zebrafish is indicative of altered neuronal 
excitability, also described in rats (129).
In metabolic disorders, the risk to develop dystonia increases 
when the manganese homeostasis is compromised. In zebrafish, 
the mutation of the orthologs of the human manganese trans-
porters, slc30a10 and slc39a14, results in manganese accumula-
tion in the brain (130, 131). This leads to impaired dopaminergic 
and GABAergic signaling. Changes in the swimming pattern 
are also visible upon exposure to manganese. The phenotype 
can be reverted by chelation therapy and iron supplementation, 
currently used in the clinical practice. Maple syrup urine dis-
ease is another metabolic disorder, caused by mutations in the 
dihydrolipoamide branched-chain transacylase E2 (DBT) gene, 
which can result in severe dystonia. In zebrafish, disruption of 
the ortholog gene results in elevated levels of branched-chain 
amino acids (BCAA) (132). This phenomenon is also evidenced 
in mammalian models and patients. The increase of BCAA leads 
to the dysregulation of the neurotransmitter glutamate in the 
brain and spinal cord of zebrafish, which probably contribu-
tes to the progressive aberrant motility behavior evidenced. 
This phenotype was suggested to represent severe dystonia in 
zebrafish larvae.
Chemical Zebrafish Models of Dystonia
Zebrafish are sensitive to neurotoxic drugs that may cause dys-
tonia. Matrine and sophocarpine, two drugs responsible for 
poisoning juvenile and infant patients, induce growth retardation 
in zebrafish (133). Exposure to these drugs also led to changes 
in spontaneous movements and locomotor performance. The 
authors suggested that this phenotype results from the neurotoxic 
effects of the drugs but did not show evidence of neurotoxicity.
In summary, it appears that the heterogeneous nature of dysto-
nia can be reproduced in zebrafish. Zebrafish offers an excellent 
opportunity to understand the pathogenic mechanisms behind 
the vast number of genetic and environmental factors linked 
to dystonia. Nevertheless, this heterogeneity seems to result in 
a large number of studies, with minor characterization and no 
consolidation of the observed phenotypes. This may undermine 
a correct judgment about the validity of zebrafish as a vertebrate 
model of dystonia. Most certainly, further studies are essential.
chorea in Huntington’s Disease
Chorea is the most common symptom of HD, which affects 
around 4–10 per 100,000 people in the western world (134). 
HD is an autosomal-dominant neurodegenerative disorder, 
which results from abnormal expansion of the CAG repeat in the 
huntingtin (HTT) gene (polyglutamine disease) (Table  1). The 
pathogenesis of HD results from the toxic effects of the mutant 
HTT RNA and protein, HTT aggregation (intranuclear inclusions 
of abnormal HTT are pathological hallmark) and impairments in 
protein homeostasis and clearance. These events lead to the death 
of GABAergic medium spiny neurons in the striatum. Chorea 
can be improved by tetrabenazine, and the therapeutic effects 
of other drugs are only empirical (120). There is currently no 
disease-modifying treatment for HD.
Genetic Zebrafish Models of HD
The zebrafish ortholog of the human HTT only encodes four 
glutamines, compared with up to 35 in humans (135). The 
zebrafish HTT protein is essential for iron, lipid, and cholesterol 
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homeostasis (136, 137), energy metabolism (136), and brain 
development (138–140). Its knockdown leads to diverse pheno-
types, including hemoglobulin deficiency (136), neuronal apop-
tosis in the midbrain and hindbrain (138, 139), neurophysiologic 
abnormalities (138–140), decreased expression of brain-derived 
neurotrophic factor (BDNF) (138), deficient formation of neural 
tubes and cell adhesion (140), increased activity of metallopro-
teinases (ADAM10 and Ncadherin) (140), and severe reduction 
in cartilage biogenesis (Table  3) (137). Consistently, patients 
with HD exhibit deficits in iron homeostasis (141, 142), energy 
metabolism (143), BDNF expression (144), and metallopro-
teinases activity (145). As observed in HTT knockout mice, the 
complete abrogation of the expression of zebrafish HTT results 
in embryonic lethality (138). In fact, the mouse models of HD 
either lack overt phenotypes or exhibit premature death (146). 
This makes the HTT morphant zebrafish a valuable alternative 
model to study the cellular function of HTT and its role in the 
pathological mechanisms of HD. Nevertheless, morpholino-
mediated knockdown may result in variable phenotypes and 
must be considered cautiously.
Zebrafish lines expressing normal and expanded polyglu-
tamine (polyQ) fragments of HTT have been reported (147, 148). 
In these lines, the misfolding, oligomerization, aggregation, 
and toxicity of the polyQ fragments are length dependent, 
in a manner similar to that observed in other animal models 
and in patients. Zebrafish embryos overexpressing fragments 
with more than 35Q repeats (mutant form) display insoluble 
protein inclusions and increased apoptosis (148). This leads to 
abnormal morphology and development. Strikingly, apoptosis 
can be detected in cells with no visible inclusions, suggesting 
that the oligomeric forms of the HTT may be the toxic com-
ponents. The ubiquitous expression of the polyQ proteins may 
contribute to the severe phenotype observed. In alternative, it 
would be interesting to observe the effects of polyQ expression 
restricted to the CNS. The toxic effects and aggregation of the 
mutant fragments can be suppressed either by the chaperones 
Hsp40 and Hsp70 or by the ubiquitin ligase C-terminal Hsp70-
interacting protein, resembling other HD models.
Remarkably, the expression of a mutated polyQ fragment 
lacking the 17 amino acids of the HTT N-terminal tail (mHTT-
ΔN17-97Q) elicits toxicity only in neuronal cells of a transgenic 
zebrafish line (149). Particularly in neurons, mHTT-ΔN17-97Q 
fragments rapidly form massive intranuclear aggregates. This 
demonstrates that the neuronal cells have lower capacity to 
maintain the proteostasis of the expanded polyQ fragments. 
Moreover, the mHTT-ΔN17-97Q fragments tend to aggregate 
more and induce a more severe phenotype than the polyQ frag-
ments with an intact N17 terminal. In mice, the expression of the 
htt-97Q gene lacking the N17 causes dramatic accumulation of 
nuclear mutant HTT aggregates and a robust striatal neurode-
generation that leads to adult-onset movement disorder (150). 
These results suggest that the N17 portion of the HTT protein 
substantially prevents the translocation of mutant HTT into the 
nucleus and plays an important role in the molecular mecha-
nisms of the pathogenesis of HD. mHTT-ΔN17-97Q transgenic 
zebrafish are the first to recapitulate one of the pathological 
hallmarks of HD.
Chemical Zebrafish Models of HD
The administration of quinolinic acid (QA) into the striatum 
of adult rodents has been used to induce brain injury that 
replicates HD (151). Interestingly, while inducing injury, this 
excitotoxin also stimulates the subventricular neurogenesis 
zone and neuroblast migration (152, 153). This observation 
encouraged Skaggs and colleagues (154) to lesion the telen-
cephalon of adult zebrafish with QA and study its neuronal 
effects. The QA induces cell death and microglial infiltration 
in the zebrafish CNS (154). However, it also stimulates cell 
proliferation and neurogenesis that results in total repair of 
the damage. The authors suggested that this zebrafish model 
is a powerful tool to study neuronal regeneration in an adult 
vertebrate and to test potential disease-modifying therapies. 
Still, the neurogenesis process in the CNS of adult zebrafish is 
very different from mammals, which might render the transla-
tion of the observations puzzling.
In general, the zebrafish HTT shares several important 
functions with the mammalian ortholog. Zebrafish lines that 
overexpress mutant HTT are proving to be useful to model HD. 
Nevertheless, there is only a shallow description of the motor 
phenotypes, and the responsiveness to pharmacotherapies still 
needs to be tested on these models.
Stereotypies in Rett Syndrome
Rett syndrome is a non-neurodegenerative disorder, which 
affects 1 in 10,000 females by the age of 12 (155). Caused by either 
nonsense or missense mutations in the methyl-CpG-bind ing 
protein 2 (MECP2) gene, RTT is characterized by hand stereotyp-
ies (Table 1). MeCP2 is a nuclear protein that recognizes DNA 
methylation to, presumably, regulate gene expression and activa-
tion. The patients with RTT, exhibit abnormally small and densely 
packed neurons, with reduced dendritic complexity and synaptic 
density. At the cellular level, alterations in different signaling and 
homeostatic pathways are reported, along with mitochondrial 
dysfunction and oxidative stress. The options available for the 
treatment of RTT are currently limited, but several compounds 
are under clinical trials. These include modulators of neurotrans-
mitters or regulators of cellular metabolism and homeostasis 
(Table 1).
Genetic Zebrafish Models of RTT
In mice, null mutations in MeCP2 drastically reduce lifespan 
(156). By contrast, zebrafish carrying a null mutation in MeCP2 
show normal viability and fertility (157). Instead, MeCP2-null 
zebrafish exhibit clear motor impairments at early developmental 
stage (Table 3). These include spontaneous and sensory-evoked 
motor anomalies, and defective anxiety-like behavior. This 
zebrafish line has a nonsense mutation in the methyl-CpG bind-
ing domain (mecp2Q63X), crucial for protein function. The authors 
suggested that the modest phenotype observed may result from 
a compensatory mechanism triggered by other proteins belong-
ing to the MeCP2 family or from gene duplication in zebrafish. 
On the other hand, the studies exploring thigmotaxis in mouse 
models of RTT have yielded confounding results, some of them 
contradictory to the ones observed in zebrafish. The authors 
advocated that the complexity of the neuronal circuitry in mice 
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There is limited understanding of the etiology of this multi-
factorial syndrome (Table 1), because several genetic variants 
and mutations, and non-genetic determinants are implicated. 
Moreover, these are not exclusive of the disease. This heteroge-
neity results in a complex and variable neurological and clinical 
phenomenology. Tourette’s syndrome is typically manifested 
by various motor and phonic chronic tics (172). The cortico–
striato–thalamocortical circuitry is potentially impaired, but 
the specific neuronal pathway(s) involved remain unknown. 
Neuroleptic drugs and the monoamine depleting drug, tetra-
benazine, are the most effective for tic suppression (Table  1). 
There exist different rodent models of tics, but their validity is 
debatable. The inability to assess several human symptomatic 
features, such as premonitory sensation, is an important limita-
tion of these animals. While the same skepticism can apply to 
zebrafish, zebrafish models of Tourette’s syndrome may help to 
elucidate the interplay between genetic and non-genetic risk 
factors. Ultimately, this may provide valuable clues about the 
neuropathology of this syndrome.
DiScuSSiON
Zebrafish have been extensively used in the study of the CNS. 
More recently, the use of zebrafish as a model of human brain 
diseases and for drug discovery has increased (2, 173). Here, 
we review several zebrafish models of movement disorders and 
discuss their translational value. Overall, these models exhibit 
conserved biochemical and neurobehavioral features. In retro-
spect, many advantages can be named, but pitfalls must also be 
highlighted.
First, all studies used zebrafish during embryonic, larval 
or young adult stage. Practical reasons can justify the use of 
zebrafish at these developmental stages. For instance, at embry-
onic and larval stage zebrafish are more permeable, enabling the 
delivery of drugs through the water. In higher vertebrates, some 
of the neurotoxic agents used to model movement disorders 
have to be delivered directly in the brain (174). This approach 
increases variability between animals and is much more inva-
sive, resulting in the death of some animals. Furthermore, the 
time lapse between drug administration and appearance of the 
first phenotypes is much longer in rodents than in zebrafish. 
Nevertheless, the use of zebrafish larvae is not as accurate as 
the use of adult zebrafish, where the BBB is fully functional and 
better mimics the mammalian physiology. The use of zebrafish 
at early developmental stages also allows to explore the function 
of specific genes during system development and maturation. 
However, it must be considered carefully when extrapolating 
the phenotypes observed to chronic and late-onset disorders. 
Moreover, the mutant and transgenic lines described here were 
characterized very early during development, and whether these 
lines display any pathology in adulthood was not reported. 
Inevitably, the brain of zebrafish is more complex at adulthood 
and may mimic more accurately the physiologic features of the 
mammalian brain.
In turn, morpholino-mediated knockdown is extensively 
used, because it is a practical tool to reveal the phenotypes 
induced by downregulation of a gene in zebrafish, but it also 
may have hampered the interpretation of the results in behavioral 
tests. Later proteomic analysis in the MeCP2-null zebrafish line 
revealed changes in the expression of proteins critical for energy 
metabolism, balance of redox status and muscle function (158). 
This is in line with the reported in RTT patients and experimental 
mouse models (159–164).
Additional studies in zebrafish confirmed the essential role 
of MECP2 in neuronal differentiation (165), axonal branching 
of primary motor neurons (166), and peripheral innervation of 
sensory neurons (167). The studies further proved that MeCP2 
regulates the expression of several cell differentiating factors 
(Id1–Her2 axis), BDNF and axonal guidance cues (such as 
Sema5b and Robo2). The indirect disruption of the expression 
of these genes is involved in RTT-like phenotypes. Accordingly, 
downregulation of MeCP2 induces a decrease in motor activity 
and impairments in the sensory function of zebrafish, as observed 
in mice with partial loss of MeCP2 (168).
All these studies strengthened the notion that the zebrafish 
MeCP2 is crucial for the regulation of gene expression and 
activation. Therefore, Mecp2-deficient zebrafish have several 
phenotypes, reminiscent of the phenomenology observed in 
mouse models of RTT and in patients with RTT. The normal 
lifespan in MeCP2-null zebrafish may enable a more profound 
characterization of the pathophysiological dynamics of RTT and 
the screening of new drugs.
Other Hyperkinetic Syndromes
Tremor is a rhythmic oscillation of a body part. Besides resting 
tremor in PD, this phenomenology is mostly common in the neu-
rologic disorder essential tremor (ET) (120). Progressive action 
tremor is the classic feature of ET. The most effective drugs for the 
treatment of ET are propranolol and primidone (Table 1) (169). 
However, these drugs induce highly variable therapeutic effects 
and are associated with several adverse effects. The anticonvul-
sant, topimarate, the GABA agonist, gabapentine, and several 
benzodiazepines have also shown to improve tremor. The patho-
logical mechanisms and etiology of ET are highly heterogeneous 
(170). In addition, these are difficult to identify, because ET is 
commonly a comorbidity. Several genetic and environmental risk 
factors have been suggested, but none was consistently confirmed 
in larger cohort studies. This renders the discovery of effective 
pharmacologic treatments particularly difficult.
Zebrafish may be a practical choice to unravel some of the 
pathological mechanisms and risk factors implicated in ET. 
This model has been used to explore the physiological role of 
TENM4 and the pathological effects of mutations identified in 
the TENM4 of families with ET. Morpholino knockdown of 
the TENM4 zebrafish ortholog results in a modest reduction of 
myelination and aberrant extension, branching and architecture 
of small axons in the CNS of zebrafish (Table 3) (171). Zebrafish 
expressing mutated human TENM4 mRNA show a similar 
phenotype. These observations are concordant with studies in 
other animal models. Since 2015, no other study reported the 
generation of a zebrafish model of tremor, possibly because of 
the limited knowledge about the nature of ET.
Perhaps for the same reason, at the time of this review, no 
zebrafish model of Tourette’s syndrome has been reported. 
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has many pitfalls. The extension of abrogation of the expression 
of the gene can vary drastically, depending on the knockdown 
strategy and efficiency. Zebrafish possess duplicates of several 
genes, which can result in a differentiated regulation of gene 
expression and different phenotypes. In addition, morpholino-
mediated knockdown has an acute and transient effect, which 
does not mimic the chronic effects of downregulation of a gene. 
On the other hand, non-specific and off-target effects are com-
mon, most of the studies lacked the right controls to rule out 
these effects and, therefore, could not exclude that other systems 
could be affected. Finally, the knockdown of a gene may not be 
suited to model some diseases. This is the case of HD, as loss 
of function of the HTT protein alone does not seem to lead 
to the disorder (175). The genetic manipulation of zebrafish is 
particularly easy and should be more exhaustively explored. The 
mutated or transgenic zebrafish lines develop rapidly, which is 
an advantage when compared with the time-consuming devel-
opment of rodent models. When developing transgenic lines, 
neuronal promoters should be used, to prevent overt toxicity 
of the transgene. This has been observed for zebrafish lines that 
overexpress human α-synuclein or HTT polyQ fragments with 
non-specific promoters (75, 148). In rodents, neuronal promot-
ers are commonly used to restrict the expression of the proteins 
to the CNS (176).
Another limitation of most of the studies is the restriction of 
the characterization of the zebrafish model to a single cellular 
biomarker or behavioral parameter. For instance, most of the 
studies in zebrafish models of PD determined the expression 
of TH to assess the integrity of the dopaminergic system, but 
DAT would be a more specific biomarker for this neuronal 
population. The zebrafish proteomics is conserved, which 
allows the use of commercially available biomarkers of other 
species. Several of these markers have already been tested on 
zebrafish targets, and many present similar reactivity. In turn, 
almost all studies limited the evaluation of behavioral changes 
to total locomotor activity and/or speed, which does not rep-
resent the multi symptomatic nature of movement disorders. 
The assessment of these parameters in zebrafish is a sound 
strategy, because they are related to the parameters used in 
rodents to depict bradykinesia. Nevertheless, zebrafish possess 
a diverse repertoire of behaviors with homology to humans, 
which have been cataloged and can be easily explored by 
experimenter-independent behavioral tracking systems (177). 
Several behavioral tests have been optimized to evaluate motor 
performance, motor coordination, balance, escape responses, 
exploratory behavior, reward/punishment-related behavior, 
learning, memory, social interaction, and aggressive or anxious 
behaviors (178–183). It is now crucial to overview the array of 
behavioral tests available for zebrafish, as it has been systemati-
cally done for rodents (184, 185).
Furthermore, similar to other models, a deeper charac-
terization of zebrafish will certainly improve the validity of this 
model system. Regardless the differences between the zebrafish 
brain and mammalian brain, homologous functions have been 
attributed to different neuronal regions of each vertebrate. This is 
the case of the zebrafish diencephalic dopaminergic region (15). 
However, other neuronal components and physiologic events 
that modulate movement are still highly unknown. It would be 
relevant to understand the cerebral components of the zebrafish 
brain that correspond to the constituents of the mammalian 
basal ganglia–thalamocortical circuits and to investigate how 
they are interconnect. Is there a direct and indirect pathway-like 
system in zebrafish? How do zebrafish control movement features 
like velocity or direction? Perhaps, to dissect these processes in 
simpler brain circuitries, as the zebrafish ones, will help to under-
stand more complex mechanisms in mammals. For instance, the 
small size of the zebrafish brain is useful for three-dimensional 
mapping of brain structures. With the up-to-date microscopic 
techniques, whole-brain neuronal connectivity can be easily 
performed in zebrafish and reveal anatomical relationships, that 
in larger brains may not be as facilitated. Another particularity 
that should be further explored is the regenerative capacity of the 
zebrafish CNS. Several neuronal proliferating sites were identified 
in the zebrafish brain as compared with two found in the mam-
malian brain (186). Notwithstanding, many of the molecular 
and cellular factors that drive regeneration in the brain of adult 
zebrafish are poorly understood and yet unknown. This may dif-
ficult the translation of disease-modifying drugs identified using 
zebrafish.
Finally, the distinctive and reproducible behaviors of zebra-
fish exposed to certain neuroactive drugs are a powerful evi-
dence of the conserved functional properties of the neuronal 
circuitries in vertebrates (187–189). In addition, it highlights 
the translational value of zebrafish. To improve the validity 
of this model, it is now important to explore the mechanisms 
triggered by these drugs on the zebrafish targets. This will 
increase our understanding of the zebrafish neuronal modula-
tion, and most importantly, enlighten the pharmacodynamic 
properties of the compounds in zebrafish. In fact, the factors 
that influence the pharmacodynamic and pharmacokinetic 
properties of drugs in zebrafish are poorly understood. For 
instance, previously, it has been assumed that zebrafish totally 
absorb and distribute through the system the small molecules 
present in the water (190). However, a recent review has sug-
gested that the absorption of chemicals, as well as distribution 
through the BBB in zebrafish is comparable to mammals (191). 
Therefore, the chemical properties of the compounds should 
be considered when extrapolating concentrations between 
these two models. The metabolism and excretion of drugs 
in zebrafish are also difficult to predict. Despite zebrafish 
have important metabolic enzymes also found in mammals 
(192), these are not fully characterized. In addition, several 
differences in the metabolism of chemicals have been reported 
(193). The compounds used in the clinic are extensively 
characterized and are particularly adequate to investigate the 
differences of these compounds on fish and mammals. This 
would also create a basis to more precisely extrapolate doses 
between both models.
Probably, a key pitfall in the discovery of new drugs in 
zebrafish is the absence of general guidelines to calculate mam-
malian equivalent doses from zebrafish doses. While between 
mammalian models there exist established formulas (194, 
195), the dose extrapolation from zebrafish to mammals is still 
empirical nowadays. Moreover, much of the existing literature 
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in vivo studies will not only improve our ability to understand 
the pathogenic mechanisms of complex diseases, as movement 
disorders but also precipitate the discovery of novel drugs for 
these disorders. Zebrafish should be considered a practical and 
inexpensive tool for this approach, provided that, as with any 
other non-mammalian model, the potential molecules selected 
in it are further validated by studies in mammals. It is not 
expected of zebrafish models of movement disorders to fully 
recapitulate such complex human phenomenology. Even mam-
malian models have their flaws and do not precisely mimic the 
symptomatology evidenced in patients. Furthermore, several 
compounds selected using the traditional models have also 
failed to demonstrate therapeutic effects in humans. Finally, it 
is vital to create a comprehensive correlation between zebrafish 
and mammalian models and, ultimately, be able to translate the 
findings to humans.
Overall, while it is already evident that zebrafish models 
of movement disorders share many cellular and physiologic 
mechanisms with mammalian models and patients, this model 
is still showing its usefulness for drug discovery. It was not 
until 2011 that a positive hit from a zebrafish-based drug 
screening entered phase I clinical trials (200). The usefulness of 
zebrafish to model human diseases will only be unquestionable 
when a drug selected in this model proves efficacy in human 
patients. Meanwhile, the use of zebrafish to study movement 
disorders will certainly result in a better understanding of 
their mechanisms and, hopefully, in the discovery of better 
therapies.
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has omitted this rationale (196–199). The only way to understand 
this rational is by increasing the number of studies where the 
properties of drugs in zebrafish are translated to mammals. Until 
now, it seems that only a minority has reached this far. It is not 
clear dough, whether there is little interest on these drugs, or 
they actually did not show the same properties in rodents and 
were not reported. The translation of the discoveries will allow 
the elaboration of a meta-analysis where the effective doses in 
zebrafish and mammals can be compared. Ultimately, it would 
boost the generation of formulas that rule dose extrapolation 
from zebrafish to different mammalian models and increase the 
validity of zebrafish models.
cONcluSiON
This review underscores the strengths and limitations of the 
zebrafish models of movement disorders developed to date. 
Importantly, it raises awareness that zebrafish can mimic the 
phenomenology of different movement disorders but needs fur-
ther characterization. To date, there are a substantial number of 
studies reporting the use of zebrafish as a model for PD. However, 
for other movement disorders, this number is still limited. 
Considering the pathological hallmarks, motor phenotypes, and 
responsiveness to pharmacotherapies, from the seven movement 
disorders reviewed here, zebrafish models have only been fully 
characterized in the context of PD. Notwithstanding, the use of 
zebrafish to model human disorders dates back to the beginning 
of the twenty-first century, which compared with the 500 years 
of use of rodent models, is at embryonic stage. This difference of 
half a century may explain the skepticism that still exists about 
the use of zebrafish as an animal model of human diseases. The 
number of studies reporting the use of zebrafish as an animal 
model is growing and, therefore, the analysis of the pros and 
cons of the use of this vertebrate model for drug discovery is 
important.
This study also provides a comprehensive assessment of 
the methodologies adopted and emphasizes that most of the 
limitations are inherent to it. Many techniques are available 
to surpass these limitations and generate consistent and well-
characterized models of movement disorders. With the next-
generation sequencing, to couple genomic approaches with 
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